Back

Safety, pharmacodynamic and pharmacokinetic characterisation of vericiguat: key results from six phase I studies in healthy subjects

26 May 2019 (08:30 - 18:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Pharmacology and Pharmacotherapy Cardiovascular Pharmacotherapy, Other HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Corina Becker

Bayer AG, Wuppertal (Germany)

12 More presentations in this session

Presentation thumbnail
Doctor J. Fallon (Cleveland, US)
Abstract Slides
Presentation thumbnail
Mr C. Moliner-Abos (Barcelona, ES)
Abstract
Presentation thumbnail
Doctor J. De Almeida (Coimbra, PT)
Abstract
Presentation thumbnail
Professor M. Ledwidge (Dublin, IE)
Abstract
Presentation thumbnail
Doctor S. Del Prado Diaz (Madrid, ES)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Pharmacology and Pharmacotherapy

The Event

Event poster

Heart Failure 2019

26 May 2019 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
28 August 2020
thumbnail
Congress Session
Editor's Choice: report from the heart failure sections of ESC Journal Family and overview of the ESC Textbook of Heart Failure
18 May 2025
thumbnail
Congress Presentation
Impaired arterial baroreflex function as a potential mechanism for riociguat-induced hypotension: insights from a baroreflex open-loop analysis in sugen–hypoxia pulmonary hypertension rats
29 August 2026
thumbnail
ESC Journals
66 Relative efficacy of sacubitril/valsartan, dapagliflozin and vericiguat: a systematic review and network meta-analysis
17 December 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources